A great number of derivatives of the natural macrolide antibiotic erythromycin A (1) have been synthesized and the structure-activity relationship described.1* 6-0-Methylerythromycin A (3; clarithromycin) and 6,1 1-di-O-methylerythromycin A (4), both possessing higher acid-stability compared to 1, exhibit excellent in vitro and in vivo antibacterial activities against Gram-positive bacteria and Mycoplasmapneumoniae.2) These results attracted us to study other 0-alkyl derivatives. In this paper we describe the synthesis and antibacterial activity of several O-alkylerythromycin derivatives, other than 3 and4.
Results and Discussion
Chemistry In the development of synthetic routes for 3, O-alkylation of 2'-0,3'-iV-bis(benzyloxycarbonyl)-iydemethylerythromycin A (2)3) has been investigated. O-Methylation of 2 with methyl iodide and 1 equiv of potassium hydroxide (KOH) in DMSO-l ,2-dimethoxyethane gave 6-0-methyl derivative (3z, 39%) and 1 1 -O-methyl derivative (8z, 51 %). Compound 8z was also obtained by the 0-methylation of2 using sodium hydride (NaH, 1.2 equiv) in DMFin 71% yield. According to the usual deprotection and reductive Af-methylation sequence,3) 3z and 8z were converted into the free bases 3 and 8, respectively. HPLC analysis indicated that the crude 3z, prepared using 1.2 equiv of base, contained another methylated product other than 3z and 6, 1 1 -di-O-methyl derivative 4z. After deprotection and subsequent iV-methylation, the corresponding unknown compound was isolated and identified as 6, 12-di-O-methylerythromycin A (5). Further methylation of 3z using 2.3 equiv of KOHgave 4z and 6,l l,4"-tri-0-methyl derivative 6z. O-Methylation of 2 with excess of methyl iodide and NaH(6 equiv) gave 6,l l,12,4"-tetra-0-methyl (7z), l l,12,4//-tri-O-methyl (lOz), and 9,l l,4"-tri-O-methyl derivative (12z). A reaction of 2 with dimethyl sulfate and NaH (2. 1 equiv) in DMFgave 8z and 1 1 ,4"-di-0-methyl derivative (9z). When methylated using respectively. ll-0-Ethyland ll-0-propylerythromycin A (13 and 14) were prepared by selective 1 1-0-alkylation of 1 with the corresponding alkyl halide and NaH. As mentioned above, O-methylation of bis-protected 2 takes place at first at the C-6 and C-l 1 positions individually, and then proceeds stepwise by the following two main pathways: (A) C-ll->C-ll, C-9 (and C-ll, C-4")->C-9, C-ll, C-4"; (B)
C-6-»C-6, C-ll-+C-6, C-ll, C-4"->C-6, C-ll, C-12, C-4". The higher reactivity of the C-6 and C-ll hydroxyl groups for Oalkylation may be associated with the structure of 2, having the steric neighboring oxygens at C-l, C-6, C-9, and C-ll, which is deduced from X-ray analysis of 1.4) The details of reaction selectivity of the C-6 and C-l l hydroxyl groups will be described elsewhere. The preliminary elucidation of the structures of 3 and 4 was previously reported.
2) The structure of other 0-alkyl erythromycin A derivatives has been well elucidated on the basis of 13C NMRspectra as shown in Table 1 . The 13C NMRspectrum of tetra-0-methyl 7 showed methoxy signals derived from the tertiary C-6 and C-12 hydroxyl groups at 50.4 and 52.9ppm, and those from the secondary C-l l and C-4" hydroxyl groups at 60.6 and 62.1 ppm, respectively.
The chemical shifts ofmethoxy groups in other O-methyl compoundswere similar to the corresponding those in 7. In addition, the signal at about 48ppm in ll and 12 was assigned to the 9-OCH3 group derived from the C-6/C-9 hemiacetal. As shown in Table 1 , the following down field shifts of a-carbon, compared to those of 1, were caused by O-methylation: C-6 (SA 3.7-4.5), C-9 (SA 1.7-1.9), C-ll (SA 9.6-ll.6), C-12 (dA 4.5-6.1), and C-4" (SA 10.5-ll.1).
The *H NMRspectrum of8 showed several pairs of signals attributed to 1 1-OCH3 (S 3.48 and 3.37), 3"-OCH3 (S 3.35 and 3.30) , and 3'-N(CH3)2 (S 2.32 and 2.30), indicating that 8 existed as a mixture of C-9 keto and C-6/C-9 hemiacetal tautomers5) with a ratio of ca. 1 : 1 in CDC13. Crystallization of 8 from acetone gave the C-9 keto tautomer whose structure has been confirmed by solid state 13C NMR spectroscopy (unpublished data).
The *H and 13C NMRspectra of 9, 13, and 14 in CDC13showed the pattern similar to those of 8, indicating the ratio of C-9 keto to C-6/C-9 hemiacetal to be ca. 1 : 1. Further, the mass spectra (FAB-MS or SI-MS) of O-alkyl erythromycin A derivatives exhibited the characteristic protonated molecular ion MAR. 1990 Chemical shift (S, ppm)a Carbon Chemical shifts are in ppm down field of TMS. 13C NMRspectra were taken in CDC13at 100.4 MHz.
peaks with the increasing mass units due to the additional alkyl groups. Acid Stability It has been reported2* that compounds 3 and 4 are more acid-resistant than 1 and the 95%of their antibacterial activities against Staphylococcus aureus 209P-JC are retained after 30 minutes in the pH2 solution. Several 0-methyl compounds (3, 4, 7, and 8) were exposed to dilute HC1 (pH2) at 20°C. The amounts of remaining substances were measured by HPLC.The t1/2 values for 3, 4, and 7 were 25.1, 16.7, and 58.3 hours, respectively, whereas those of 1 and 8 were 0.03 and 0.02 hour, respectively. The position, in addition to the C-6 position, resulted in a further increase of acid-stability. In Vitro Antibacterial Activity Compound
The in vitro antibacterial activities of O-alkyl erythromycin A derivatives are shown in Table 2 .
Compounds 3 and 5 exhibited excellent activities and were equal to or 2-fold more potent than 1. The methylation of the tertiary hydroxyl groups at C-6 or C-6 and C-12 resulted in no change or an increase of in vitro activity. NZ:Nomeasurable zone of inhibition in microbiological assay. hydroxyl groups at C-ll or C-4" resulted in a decrease of the in vitro activity as reported6) for the esterification of 1. The activities of O-methyl derivatives decreased with increasing the number or the chain length of the alkyl groups introduced. The activities of ll and 12, both having the 9-0-methyl-6,9-hemiacetal structure,
were 32-to 500-fold less than that of 1.
In Vivo Antibacterial Activity The representative O-methyl compounds (3, 4, 5, and 8), possessing potent in vitro activity against S. aureus Smith 4, were advanced to in vivo trials against a systemic infection of the same organism in mice. As shown in Table 3 , compounds 3, 4, and 5 were 3.6~7.6, 2.2, and 3.0 times more effective than 1, respectively. The efficacy of 8 was comparable to that of 1. The improved therapeutic efficacy provided by 6-O-methyl derivatives may be related to the better absorption of these compounds after po administration.
Lung and Plasma Levels
The lung and plasma levels of compounds 3 and 5 were compared to those of 1 after po administration (20mg/kg) in rats. The concentrations of 3 and 5 were 9 to ll times higher than that of 1 in plasma and 122 to 188 times higher in lung at 2 hours after administration (Table 4) . These concentrations remained at fairly high levels after 4 hours, while those of 1 were under the limit of detection. It has been reported7) that affinities of 0-alkyl derivatives to the lung tissues are higher in order of 7>6>3=4>8>l. These results indicate that methylation of the tertiary hydroxyl groups at C-6 and/or C-12 of 1 contribute to the penetration of drugs to the lung. Experimental MP's were taken using a Yanagimotomicro-melting points apparatus and are uncorrected. IR spectra were recorded on a Jasco DS-701G IR spectrometer. FD-MS, HREI-MS, and SI-MS were recorded on a Hitachi M-80Amass spectrometer, and FAB-MSwere on a Jeol JMS-SX102 mass spectrometer. XH and 13C NMRspectra were recorded in CDC13on Varian XL-200 or Jeol JNM-GX400 spectrometers. The XH and 13C assignments were determined by INEPT and^^H or^-^C shift correlation 2D NMR spectra. Optical rotations were determined with a Jasco DIP-360 digital polarimeter. TLC was performed on E. Merck plates of Silica gel 60 using solvent systems A (EtOAc-hexane, 2 : 1) or B (CHC13 -MeOH-NH4OH, 8 : 2 : 0.01). Spots were visualized by spraying with 2%eerie sulfate -2n H2SO4solution followed by heating at 1 10°C. Silica gel column chromatography was performed with Silica gel 60 or Silica gel 60 silanised (70~230 mesh, E. Merck).
In Vitro and In Vivo Antibacterial Activities
Antibiotic susceptibility was determined by an agar dilution method using Sensitivity Test Agar (Eiken). Mouse protection experiments were conducted by use of male ICR mice infected intraperitoneally with S. aureus Smith 4. The antibiotics in a 5% gum arabic were administered orally 1 hour after the infection. Mortality of the animals was recorded daily over a period of 7 days and ED50was calculated.
Plasma and Tissue Levels
The antibiotics in a 5% gum arabic were administered orally to rats with the dosing of 20mg/kg. The rats were sacrificed at 2 and 4 hours after administration. The lung was homogenized with 0.02m phosphate buffer (pH 7.4) -MeOH(1 : 4). The concentrations of the antibiotics in lung and plasma were measured by a microbiological assay using Micrococcus luteus ATCC9341.
General Procedure 1 for O-Alkylation of Erythromycin Derivatives
To a well stirred solution of the substrate in a solvent (5~20ml/g substrate) at 0~5°C, were added successively the alkyl halide (1.2~8 equiv) and the base (1~6 equiv). The mixture was stirred for 0.5~2 hours at 0~5°C. At the end of the reaction, Et3N (excess to alkyl halide) was added to quench the reaction. The reaction mixture waspoured into water and extracted with EtOAc.The organic layer was washed several times with brine, dried over anhydrous MgSO4,and evaporated in vacuo to which was purified by silica gel column chromatography. O-Alkylation was carried give/the c out using rude product the following reaction solvents and bases: DMF, DMSO-THF(1 : 1) or DMSO-1,2-dimethoxyethane (1 : 1); NaH (50 or 60%, coated with mineral oil), KOH(85%, freshly powdered).
General Procedure 2 for Deprotection and Reductive 7V-Methylation A mixture of the substrate (0.01 mol) and 0.5 g ofpalladium black (or 1.0g of 10% Pd-C) in a mixture ofEtOH (150 ml) and water (17.5 ml) containing 0.78 g ofAcOH and 2.5 g ofAcONa was stirred vigorously for 7 hours at ambient temperature under atmospheric pressure of hydrogen. After the complete absence of the substrate, 35%aqueous HCHO (10ml) was added, and the hydrogenation was continued for an additional 7 hours. The catalyst was filtered off and the filtrate was poured into water (750ml). The pH of the mixture was adjusted to 10~10.5 with 2n NaOHto afford the corresponding 3'-dimethylamino derivative as a precipitate which was then collected by filtration or extracted with organic solvent. The crude product was purified by silica gel column chromatography or by recrystallization. Compound 23) (120g, 0.12mol) was treated with methyl iodide (45.6g, 0.32mol) and 85% KOH (7.52g, 0.llmol) in 800ml of DMSO-1,2-dimethoxyethane (1 : 1) according to the procedure 1. The resulting crude product was purified by silica gel column chromatography (EtOAc -hexane, 1 : 2) to give 47.4g (39%) of3z (purity 94% by HPLC) and 50.5g (42%) of8z and 18.0g (15%) of the starting 2. One g of 3z was further purified by silica gel column chromatography (CHC13 -MeOH,100 : 1) and crystallized from EtOH-water (2: 1), affording 0.78g of pure 3z: MP 110-111°C; TLC (system A) Rf0.72; IR (KBr) 
O-Methylation of 2 (30g, 0.03mol) with methyl iodide (17.1 g, 0.12mol) and 85% KOH(2.38g, 0.036mol) in 600ml ofDMSO-1,2-dimethoxyethane
(1 : 1) by the procedure 1 gave 13.7g (45% yield) of MAR. 1990 3z (purity 70% by HPLC). Deprotection and reductive N-methylation of this substance (10 g) were carried out according to the procedure 2. The resulting product was suspended in ether (500ml) and stirred for 5 hours. The ether layer was separated by filtration and evaporated. The residue was crystallized from EtOH to give 4.6g (28% from 2) of 3 as colorless needles: MP 225~227°C (literature2) 222~225°C). The mother liquor was evaporated to dryness to give a foam (1.6g). One g of this foam was chromatographed over reversed phase silica gel column with 0. 1 m phosphate buffer (pH 7.0) -MeOH(2 : 3). The eluate showing Rf 0.26 by TLC (E. Merck plates of silanised Silica gel 60; 0.1 m pH7.4, phosphate buffer-MeOH,2 : 3) was evaporated to remove the most of MeOH.The resultant mixture was basified (pH9) using Na2CO3 and extracted with CHC13. The CHC13layer was washed with water, dried over MgSO4, and evaporated in vacuo to afford 0.12g (1.1% from 2) of 5 which was crystallized from EtOH to give colorless needles: TLC (system B) H 9.39, N 1.84. Found: C 61.39, H 9.53, N 1.74. 6, 1 1-Di-O-methylerythromycin A (4) and 6, l l,4"-Tri-0-methylerythromycin A (6) A solution of3z (6 g, 6mmol) in 120ml ofDMSO -1,2-dimethoxyethane (1 : 1) was treated with methyl iodide (4.56g, 32mmol) and 85% KOH (0.95g, 14mmol) according to the procedure 1. The product was purified by silica gel column chromatography (EtOAc-hexane, 1 : 1) to give 3.27g (54%) of 4z (Rf 0.72, system A) and 1.67g (27%) of6z (Rf 0.78, system A).
Deprotection and iV-methylation of 4z (1 g) and 6z (1.6g) by the procedure 2 gave 4 (0.64g, 85%) and 6 (0.63 g, 52%), respectively. 4 was crystallized from CH2C12 -ether: MP 252~257°C (literature2) 252~256°C). 6 was crystallized from CHC13 -hexane: MP229~230°C; TLC (system B) Rf0.49; IR (KBr) cm"1 1730, 1700; FAB-MS m/z 776 (M+H)+; XH NMR(400MHz, CDC13) 3 3.59 (s, ll-OCH3), 3.54 (s, 4"-OCH3), 3.32 (s, 3"-OCH3), 3.1 1 (s, 6-OCH3), 2.26 (s, N(CH3)2), 1.41 (s, 6-CH3); 13CNMR: SeeTable 1. 6,l l, 12,4"-Tetra-O-methylerythromycin A (7) and l l ,12,4"-Tri-O-methylerythromycin A (10) 0-Methylation of 2 (10g, 10mmol) with methyl iodide (13.7g, 96mmol) and 50% NaH (2.88g, 60mmol) in DMF (80ml) by the procedure 1 and silica gel column chromatography (EtOAc-hexane, 1 : 1-1 :2) of the product gave 2.95g (ca. 28%) ofa mixture of7z and lOz (Rf0.80, system A) and 5.7g (55%) of 12z (Rf 0.83, system A). Deprotection and Af-methylation of the mixture by the procedure 2 gave 1.13g (14% from 2) of 7 which was crystallized from CHC13-petroleum ether: MP 238.5~240°C (dec); TLC (system B) Rf0.49; IR(KBr) cm" 1 1727, 1710; FAB-MS m/z 790 (M +H)+; 1H NMR(400 MHz, CDC13) 8 3.54 (s, 4' -OCH3), 3.49 (s, ll-OCH3), 3.34 (s, 12-OCH3), 3.33 (s, 3"-OCH3), 3.13 (s, 6-OCH3), 2.3Q (s, N(CH3)2), 1.41 (s, 6-CH3); 13C NMR: See Table 1 ; AnalCalcd for C41H75NO13 : C 62.33, H 9.57, N 1.77. Found: C 61.92, H 9.62, N 1.76. After the filtration of 7, the mother liquor was evaporated to dryness. The residue was chromatographed on a silica gel column with MeOH-CHC13(1 :49-1 :9) to give further 0.42g (5% from 2) of7 l l ,4"-Di-0-methylerythromycin A (9) O-Methylation of 2 (2g, 2mmol) with dimethyl sulfate (lml, 10.5mmol) and 50% NaH (0.2g, 4.2mmol) in DMF(20ml) was carried out according to the procedure 1. Purification of the product by silica gel column chromatography (EtOAc-hexane, 1 : 1) gave 0.3g (15%) of 8z and 0.63g (31%) of 9z (Rf 0.67, system A). Debenzylation and JV-methylation of 9z (0.6g, 0.6mmol) by the procedure 2 gave 0.23g (51%) of 9 as a colorless foam: MP 98~99°C; TLC (system B) Rf 0.46; IR (KBr) cm"1 1730; FAB-MS m/z762 (M+H)+; XH NMR(200 MHz, CDC13) 3 3.55 (3,H, 4"-OCH3), 3.49, 3.38 (3H, ll-OCH3), 3.34, 3.30 (3H, 3"-OCH3), 2.33, 2.29 (6H, N(CH3)2), 1.45, 1.41 (3H, 6-CH3); 13C NMR (50 MHz, CDC13) 3 217.8, 108.0 (C-9), 177.3, 176.2 (C-l), 105.0, 102.3 (C-l' ), 97.7, 96.2 (C-l"), 88.9, 88.7 (C-4"), 62.1, 62.0
